makers of semaglutide FDA Warns on Certain Forms Compounded Chinese companies turn to generics

Discussion The global diabetes epidemic, affecting approximately 828 million adults in 2022 32 , has driven widespread adoption of GLP-1 RAs due to their dual glycemic and weight management benefits 33,34,35

We encourage patients to consult with our experienced healthcare providers to explore how Semaglutide GLP-1, alongside lifestyle changes, can be part of an effective strategy for achieving and maintaining a healthy weight

Oral Wegovy (25mg daily tablet) was FDA-approved in December 2025 and launched January 2026

There have been studies where people are getting off of these medications for various reasons and the weight starts to creep back up, says Andrea Bedrosian, MD, director of bariatrics at North Shore University Hospital and Long Island Jewish Medical Center

Official Details: Medication: Tirzepatide (identical to Mounjaro) Manufacturer: Eli Lilly FDA Approval: November 2023 Approved For: Chronic weight management in adults with obesity or overweight with weight-related conditions Dosing: Once-weekly injection Available Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg List Price: $1,069 per month (same as Mounjaro) How Zepbound Differs from Mounjaro: The medications are completely identical